| 1. |
孫豐森, 張世鵬, 許述. 4 種抗癲癇新藥的研究和開發. 國際藥學研究雜志, 2018, 45(11): 845-851.
|
| 2. |
Leo A, Giovannini G, Russo E, et al. The role of AMPA receptors and their antagonists in status epilepticus. Epilepsia, 2018, 59(6): 1098-1108.
|
| 3. |
Wright SK, Wilson MA, Walsh R, et al. Abolishing spontaneous epileptiform activity in human brain tissue through ampa receptor inhibition. Ann Clin Transl Neur, 2020, 7(6): 883-890.
|
| 4. |
Niu HX, Wang JZ, Wang DL, et al. The orally active noncompetitive ampar antagonist perampanel attenuates focal cerebral ischemia injury in rats. Cell Mol Neurobiol, 2018, 38(2): 459-466.
|
| 5. |
《藥學與臨床研究》編輯部 編譯. 2014 年美國上市新藥選編. 藥學與臨床研究, 2015, 23(1): 87-96.
|
| 6. |
Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther Drug Monit, 2018, 40(5): 526-548.
|
| 7. |
De Liso P, Moavero R, Coppola G, et al. Current role of perampanel in pediatric epilepsy. Ital J Pediatr, 2017, 43(1): 51-56.
|
| 8. |
Tsai JJ, Wu T, Leung H, et al. Perampanel, an ampa receptor antagonist: From clinical research to practice in clinical settings. Acta Neurol Scand, 2018, 137(4): 378-391.
|
| 9. |
Takenaka O, Ferry J, Saeki K, et al. Pharmacokinetic/ pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. Acta Neurol Scand, 2018, 137(4): 400-408.
|
| 10. |
Yamamoto Y, Usui N, Nishida T, et al. Therapeutic drug monitoring for perampanel in japanese epilepsy patients: Influence of concomitant antiepileptic drugs. Ther Drug Monit, 2017, 39(4): 446-449.
|
| 11. |
Krauss GL, Perucca E, Kwan P, et al. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase iii randomized trials: Study 307. Epilepsia, 2018, 59(4): 866-876.
|
| 12. |
Villanueva V, Garces M, Lopez-Gonzalez FJ, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The fydata study. Epilepsy Res, 2016, 126: 201-210.
|
| 13. |
Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia, 2016, 57(7): 1120-1129.
|
| 14. |
Brodie MJ, Stephen LJ. Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy. Epilepsy Behav, 2016, 54: 100-103.
|
| 15. |
Yeon KS, Joong KW, Hyuna K, et al. Clinical experience with perampanel in intractable focal epilepsy over 12 months of follow-up. Journal of epilepsy research, 2018, 8(2): 61-65.
|
| 16. |
De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies an italian observational multicenter study. Epilepsy Res, 2016, 127: 93-100.
|
| 17. |
Rohracher A, Zimmermann G, Villanueva V, et al. Perampanel in routine clinical use across europe: Pooled, multicenter, observational data. Epilepsia, 2018, 59(9): 1727-1739.
|
| 18. |
Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month general study. Epilepsia, 2018, 59(9): 1740-1752.
|
| 19. |
Swiderska N, Tan HJ, Rajai A, et al. Effectiveness and tolerability of perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study. Seizure Eur J Epilep, 2017, 52: 63-70.
|
| 20. |
Juhl S, Rubboli G. Perampanel as add-on treatment in refractory focal epilepsy. The dianalund experience. Acta Neurol Scand, 2016, 134(5): 374-377.
|
| 21. |
Nishida T, Lee SK, Inoue Y, et al. Adjunctive perampanel in partial-onset seizures: Asia-pacific, randomized phase iii study. Acta Neurol Scand, 2018, 137(4): 392-399.
|
| 22. |
Chang FM, Fan PC, Weng WC, et al. The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure Eur J Epilep, 2020, 75: 82-86.
|
| 23. |
Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with lafora disease. Epilepsy Behav, 2016, 62: 132-135.
|
| 24. |
Crespel A, Gelisse P, Tang NPL, et al. Perampanel in 12 patients with unverricht-lundborg disease. Epilepsia, 2017, 58(4): 543-547.
|
| 25. |
Ishikawa N, Tateishi Y, Tani H, et al. Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo scn1a mutation. Seizure, 2019, 71(1): 20-23.
|
| 26. |
Steinhoff BJ, Bacher M, Kurth C, et al. Add-on perampanel in lance-adams syndrome. Epilepsy Behav Case Rep, 2016, 6: 28-29.
|
| 27. |
Heyman E, Lahat E, Levin N, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol, 2017, 59(4): 441-444.
|
| 28. |
Rohracher A, Kalss G, Leitinger M, et al. Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data. Ther Adv Neurol Diso, 2016, 9(6): 445-453.
|
| 29. |
Maurousset A, Limousin N, Praline J, et al. Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in tours. Epilepsy Behav, 2016, 61: 237-241.
|
| 30. |
Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav, 2017, 66: 64-67.
|
| 31. |
Trinka E, Steinhoff BJ, Nikanorova M, et al. Perampanel for focal epilepsy: Insights from early clinical experience. Acta Neurol Scand, 2016, 133(3): 160-172.
|
| 32. |
Hansen CC, Ljung H, Brodtkorb E, et al. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: Focus on topiramate, levetiracetam, and perampanel. Behav Neurol, 2018: 2064027.
|
| 33. |
Meador KJ, Yang HC, Pina-Garza JE, et al. Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia, 2016, 57(2): 243-251.
|
| 34. |
Liguori C, Izzi F, Manfredi N, et al. Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. Epilepsy Behav, 2018, 80: 173-176.
|
| 35. |
Garamendi-Ruiz I, Garcia-Garcia ME, Bertol-Alegre V, et al. One-year clinical experience of perampanel in spain: A multicentre study of efficacy and tolerability. Epileptic Disord, 2016, 18(2): 173-186.
|
| 36. |
Meschede C, Witt JA, Rademacher M, et al. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure-Eur J Epilep, 2018, 58: 141-146.
|
| 37. |
Stefanovic S, Jankovic SM, Novakovic M, et al. Pharmacodynamics and common drug-drug interactions of the third-generation antiepileptic drugs. Expert Opin Drug Met, 2018, 14(2): 153-159.
|
